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Lysosomal storage disorders (LSDs) occur at a frequency of 1 in every 5,000 live births and are a common cause 
of pediatric neurodegenerative disease. The relatively small number of patients with LSDs and lack of validated 
biomarkers are substantial challenges for clinical trial design. Here, we evaluated the use of a commercially 
available fluorescent probe, Lysotracker, that can be used to measure the relative acidic compartment volume of 
circulating B cells as a potentially universal biomarker for LSDs. We validated this metric in a mouse model of 
the LSD Niemann-Pick type C1 disease (NPC1) and in a prospective 5-year international study of NPC patients. 
Pediatric NPC subjects had elevated acidic compartment volume that correlated with age-adjusted clinical sever-
ity and was reduced in response to therapy with miglustat, a European Medicines Agency–approved drug that 
has been shown to reduce NPC1-associated neuropathology. Measurement of relative acidic compartment vol-
ume was also useful for monitoring therapeutic responses of an NPC2 patient after bone marrow transplanta-
tion. Furthermore, this metric identified a potential adverse event in NPC1 patients receiving i.v. cyclodextrin 
therapy. Our data indicate that relative acidic compartment volume may be a useful biomarker to aid diagnosis, 
clinical monitoring, and evaluation of therapeutic responses in patients with lysosomal disorders.
Introduction
Lysosomal storage disorders (LSDs) are a group of more than 60 
inborn errors of metabolism that result in the expansion of the 
late endosomal/lysosomal (LE/Lys) compartment in cells (1–3). 
We therefore hypothesized that measuring relative LE/Lys volume 
could serve as a potentially universal biomarker for this family of 
disorders. To test this hypothesis, we developed an assay using the 
fluorescent probe Lysotracker, a weakly basic amine that selective-
ly builds up in the acidic compartment (i.e., LE/Lys). This probe 
can be visualized and quantified in circulating cells and has pre-
viously been reported in a single clinical case study of a patient 
with adult-onset Niemann-Pick type C disease (NPC) (3). NPC1 
is a progressive neurodegenerative LSD caused by mutations in 
either NPC1 or NPC2 (4). Diagnosis of NPC, which is technically 
challenging, is often delayed. There is currently 1 European Medi-
cal Association–approved disease-modifying therapy, miglustat, 
which is licensed for treating the CNS manifestations of NPC1, 
combined with symptomatic management (5, 6). At the time of 
the clinical trial of miglustat, there were no validated biomarkers 
for NPC that could be used as secondary endpoints in support 
of clinical data. Recently, oxysterols emerged as the first validated 
biochemical biomarker for NPC (7, 8).
In this study, we optimized the Lysotracker assay and validated 
it in a prospective study of more than 100 NPC patients derived 
from multiple independent clinical cohorts to ensure statistical 
power. We used this disorder as proof of concept for its use in 
other LSDs, due to the relatively large number of patients avail-
able to study with this specific lysosomal disorder. We applied this 
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with enough power (in this case, 3 mice per group per time point). 
We quantified Lysotracker fluorescence — calibrated using fluo-
rescent microbead standards and expressed as mean equivalent 
of fluorescence (MEFL) — and observed a progressive increase 
in relative acidic compartment volume (Figure 1, A and B). 
This expansion of LE/Lys was seen at all ages compared with age-
matched controls and was highly significant at each time point 
in both splenic and circulating B cells (P < 0.001). We have previ-
ously shown that B cells from Npc1–/– store high levels of glyco-
sphingolipids (GSLs) when measured by HPLC (9). A key finding 
was that peripheral B cell storage, as indicated by MEFL, paral-
leled progressive ganglioside and lactosylceramide storage in the 
brain, as measured by HPLC (Figure 1, C and D), which indi-
cates that the rate of storage in B cells in the periphery parallels 
storage in the CNS. The probe LipidTOX, which detects phos-
pholipid storage, detected phospholipids in control and Npc1–/– 
B cells, but did not show enhanced staining in Npc1–/– relative to 
wild-type B cells (Supplemental Figure 1B; supplemental mate-
rial available online with this article; doi:10.1172/JCI72835DS1), 
and thus was not further evaluated.
assay to small, resting, circulating B cells because they can read-
ily be identified as a uniform population using the CD19 marker 
and do not change in response to infection. Circulating B cells are 
therefore a suitable cell type to analyze in longitudinal studies. We 
found here that this biomarker correlated with age-adjusted clini-
cal severity scores and was responsive to miglustat therapy. It also 
correlated with levels of oxysterol (an NPC-specific biochemical 
biomarker; ref. 7) in the same patient samples. This biomarker also 
showed utility in monitoring response to bone marrow transplan-
tation (BMT) in an NPC2 patient and identified an unanticipated 
adverse event in NPC patients receiving cyclodextrin therapy with 
i.v. 2-hydroxypropyl-β-cyclodextrin (HPβCD). Taken together, our 
data support the use of this biomarker in clinical monitoring of 
NPC. In addition, this assay has the potential to be a universal 
monitoring tool for any disease with lysosomal hypertrophy.
Results
Assay validation in a mouse model. We first validated the assay in 
resting B cells (splenic and circulating) from Npc1–/– mutant mice 
using the minimal group size to provide statistically valid results 
Figure 1
Relative LE/Lys volume increases progressively in B cells in a mouse model of NPC1 disease and parallels the rate of GSL storage in the brain. 
(A and B) Splenic (A) and circulating (B) B cells were analyzed by flow cytometry over the lifespan of the Npc1–/– mouse (3 weeks, presymptom-
atic; 6 weeks, early symptomatic; 9 weeks, late symptomatic) and compared with wild-type Npc1+/+ controls. A pan–B cell marker was detected 
using an anti-CD19 monoclonal antibody conjugated to PE, and cells were costained with Lysotracker green. Analysis was performed on gated 
B cells (CD19+), and Lysotracker staining levels were standardized to fluorescent microbeads conjugated to defined numbers of fluorescent mol-
ecules/bead to linearize the logarithmic data collected by the cytometer. There was progressive elevation in B cell MEFL at each time point relative 
to the previous age point (P < 0.01, spleen, all ages, and blood, 6 and 9 weeks). (C and D) GSL analysis, performed by HPLC, of GM2 ganglioside 
(C) and lactosylceramide (D) in the forebrain of 2-, 4-, 7-, and 9-week-old Npc1–/– mice compared with wild-type controls. **P < 0.01; ***P < 0.001.
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patients also had elevated levels of MEFL above the age-matched 
control range. The youngest NPC1 subjects with significant clini-
cal manifestations had the highest MEFL values (P < 0.05, 0–6 
years vs. 13–18 years; P < 0.01, 0–6 years vs. ≥19 years). In contrast, 
the adult NPC1 patients (with later onset and slower disease pro-
gression) and the heterozygous carriers did not differ significantly 
from age-matched controls at the population level (Figure 2A).
Characterization of the study cohort. To better characterize the study 
cohort, clinical severity scores (for which higher scores denote 
Assay validation in patient blood samples. The Lysotracker assay 
was then applied to peripheral blood B cells from NPC patients. 
Although this assay would in practice be used for monitoring indi-
vidual patients over time, we had the opportunity here to evaluate 
this biomarker at the population level. We found that MEFL val-
ues were significantly elevated in B cells from the majority of pedi-
atric NPC1 patients (aged 0–12 years; P < 0.001; Figure 2A); only 
4 cases in the 0–6 year age range and 6 cases in the 7–12 year age 
range overlapped with control values. 2 infantile Tay-Sachs disease 
Figure 2
Relative LE/Lys volume identifies pediatric patients with NPC1 disease. Data were collected prospectively on NPC1 patients (n = 97, aged 
2 months to 53 years), heterozygous carriers (NPC Het; n = 40, aged 23 to 76 years), age-matched controls (n = 53, aged 4 months to 64 years), 
and 2 pediatric patients with Tay-Sachs disease (TS). (A) Lysotracker values from circulating B cells were measured by flow cytometry and plotted 
against patient age. Each patient only appears once, standardized to the first sample analyzed for each patient. ***P < 0.01. (B) When the same 
patients’ data were plotted as unadjusted severity score (with higher value denoting greater disease burden) against age, multiple subgroups were 
identified. These were designated according to decreasing severity, from the severest (subgroup a) to the mildest (subgroup f). Rate of change 
per year is indicated for each subgroup. (C) Total severity score (without hearing, as this was not measured by all clinical centers) for each patient 
was divided by patient age to generate ASIS. When plotted against MEFL, a statistically significant correlation was found (P = 0.017). (D) When 
each patient’s plasma cholestane-3β,5α,6β-triol level was plotted against their MEFL value, a statistically significant correlation was observed 
in all patients (P < 0.01). A piecewise linear model significantly improved the goodness-of-fit with respect to a single linear model (P < 0.001); in 
this model, the initial slope was significant (P = 0.015), and the second was not (P = 0.228), with the estimated change point being 21,269 MEFL.
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plasmas and found a significant correlation in NPC1 patients 
(P = 0.015), but not in controls or heterozygous carriers (Figure 2D).
Response to treatment with miglustat. Longitudinal data were col-
lected on 38 patients that were untreated, chronically treated 
with miglustat (>6 months; ref. 5), or analyzed both before and 
after miglustat therapy, with the first point being pretreatment 
(referred to herein as pre-post analysis) (Table 1). There were no 
significant differences in median ages for the 3 groups (P = 0.09). 
Of the untreated patients, 86% had positive slopes (progression of 
storage), compared with 71% in the chronically miglustat-treated 
group and 43% in the pre-post group (Table 1 and Figure 3). 
Untreated adult controls (variable MEFL values) with repeat mea-
sures were analyzed, and no significant slopes were detected (Fig-
ure 3 and Supplemental Figure 7).
Response to BMT in an NPC2 patient. An NPC2 patient was analyzed 
before and after BMT. Prior to BMT (and before immunosuppres-
sive conditioning), the patient’s MEFL value approximated the 
increasing severity; ref. 10) were plotted against patient age. Hear-
ing was excluded, as it was not measured in all clinical centers. 
There was no simple linear or nonlinear model that adequately rep-
resented the complete data distribution (Supplemental Figure 2). 
We therefore looked for discrete subpopulations of patients and 
identified 6 subgroups (denoted a–f), with subgroups b, c, and d 
defined by latent class mixture modeling (Figure 2B). The study 
cohort included miglustat-treated patients, which were repre-
sented in all 6 subgroups (Supplemental Figures 3 and 4). Sei-
zures are a common feature in the most severely affected patients; 
consistent with this, patients with seizures were almost exclusively 
present in subgroups a–c (Supplemental Figure 5). When a small 
number of untreated patients were plotted longitudinally, they 
remained within the same subgroup (Supplemental Figure 6), 
which suggests that these subgroups may have prognostic value. 
When MEFL values were plotted against total clinical severity 
score, no significant correlation was observed in the group as a 
whole or in subgroups a–f (data not 
shown). As disease progression has 
been reported to be linear in NPC 
disease (10), and different patients 
achieved their severity scores over 
variable numbers of years (Figure 
2B), total severity scores were divid-
ed by age to give an annual severity 
increment score (ASIS). When ASIS 
was plotted against MEFL, a sig-
nificant correlation was observed 
for the total NPC1 population 
(P = 0.017; Figure 2C), but not after 
stratifying by latent subgroups a–f, 
as these were individually under-
powered (data not shown).
Relationship to oxysterols. Oxysterols 
have been validated as NPC-specific 
biochemical biomarkers (7, 8). We 
therefore measured cholestane-
3β,5α,6β-triol and MEFL in matched 
Table 1
Miglustat treatment slows the rate of storage in NPC1 patients
Treatment and  Median age at first Subjects  Positive Negative No Median slope 
clinical status measurement (yr) analyzed (n) slope (n) slope (n) slope (n) (MEFL/yr)
NPC1 untreated 9.8 7 6 0 1 4,436
NPC1 chronic miglustat 10.9 17 12 3 2 1,849A
NPC1 pre-post miglustat 9.5 14 6 4 4 1,010B,C
Untreated adult controls 43.0 14 6 4 4 998
There was no significant difference in the median ages for the 3 NPC1 patient groups (P = 0.65, Kruskal-
Wallis test). Ages were not available for all adult controls, but were >18 and <65 years; median based on  
n = 6. Slopes were calculated from each patient’s longitudinal data, based on ≥2 repeat measures (untreat-
ed, 2–4; pre-post, 2–5; chronic miglustat, 2–6) over time up to 3.0 years (median, last measurement up to 
10.92 months after first sample analyzed). Given the small number of repeat measurements, rather than 
calculating a P value for each individual slope, subjects with a ±10% difference between first and last MEFL 
were defined as stable (no slope). A logistic regression model showed a significant difference between the 
proportion of positive slopes (NPC1 untreated, 86%; NPC1 chronic miglustat, 71%; NPC1 pre-post miglu-
stat, 43%) and nonpositive slopes between the untreated and pre-post groups (P = 0.05). Overall, median 
slopes from the 3 patient groups were significantly not homogeneous (P = 0.03, Kruskal-Wallis test).  
AP = 0.11 vs. untreated; BP = 0.029 vs. untreated; CP = 0.13 vs. treated; Wilcoxon-Mann-Whitney tests with 
Benjamini-Hochberg correction for multiple comparisons.
Figure 3
Miglustat treatment reduces lysosomal storage in NPC1 patients’ B 
cells. Box plots summarizing progression of storage for untreated (n = 7), 
chronic miglustat (n = 17), and pre-post miglustat (n = 14) patient 
groups as well as adult controls (n = 14) analyzed over time. The box 
is limited by the 1st and 3rd quartiles (Q1 and Q3), and the median 
is indicated by a bar inside the box; whiskers and outliers are defined 
in terms of 2 unmarked boundaries defined using Tukey’s rule as 
Q1 – 1.5 IQR and Q3 + 1.5 IQR (IQR, interquartile range, i.e., Q3 – Q1). 
Whiskers extend to the smallest and largest observed values within the 
boundaries, and outliers are defined as points outside the boundaries. 
Adjusted pairwise multiple comparisons are shown (Wilcoxon-Mann-
Whitney test). See Table 1 and Supplemental Figure 7.
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this point, 2 equally abundant (50:50) subpopulations of B cells 
were detected, which were classified as high or low MEFL staining 
(Figure 4A). This coincided with the development of 50% donor 
chimerism, based on human leukocyte analysis (data not shown).
Unanticipated potential adverse response to HPβCD treatment. Final-
ly, we investigated the effects of HPβCD therapy on B cell MEFL, 
both pre-post i.v. HPβCD therapy in 4 pediatric NPC1 patients 
(patients 1–4) and after i.v. HPβCD therapy in 2 additional indi-
viduals (patients 5 and 6); all 6 were being treated under individual 
patient Investigational New Drug (IND) provisions (Figure 4B). In 
patients 1–4, pre-post analysis showed a dramatic increase in B cell 
MEFL values in response to HPβCD treatment, with patients 1–3 
exceeding the NPC patient range. Analysis of patients 5 and 6 after 
HPβCD therapy showed MEFL values similar to those of patients 
1–3. In patients 1–4, B cells were isolated, and all 4 had increased 
levels of GSL storage after HPβCD treatment (Figure 4C). We also 
analyzed a single patient pre-post approximately 1 year of intra-
thecal HPβCD therapy (patient 7). Despite being well managed on 
miglustat, with a MEFL value in the normal pediatric range prior 
to intrathecal HPβCD treatment, patient 7 also showed increased 
MEFL values in response to HPβCD, albeit not as great as those in 
patients 1–6 with i.v. administration (Figure 4B).
Discussion
In addition to disease-specific biomarkers (7), it would be useful 
to have a general biomarker for measuring the degree of storage 
in all lysosomal disorders, regardless of the biochemical nature 
of the stored macromolecule(s). We therefore selected the probe 
Lysotracker to study, as it measures relative acidic compartment 
volume in live cells. An increased Lysotracker value could reflect 
lysosome enlargement, increased number of lysosomes, or both.
We first validated this assay in Npc1–/– mutant mice and found 
that the rate of storage in the brain and circulating B cells mirrored 
each other; thus, measuring storage in circulating B cells is a suit-
able surrogate for measuring progression of storage in the brain. 
This suggests that although absolute amounts of lipid storage dif-
fer in different cell types in NPC, the rate of storage is similar in 
average for NPC1 patients of a similar age (Figure 4A). At 1 month 
after BMT, the B cell MEFL was reduced, and by 3 months after 
BMT, it had moved into the control range (Figure 4A), suggestive 
of cross correction and/or cell replacement with donor cells. At 
Figure 4
Relative LE/Lys volume is a sensitive measure of response and poten-
tially adverse response to NPC disease therapeutics. (A) Pre-post 
analysis of an NPC2 patient with BMT, using Lysotracker analysis 
of circulating B cells. MEFL was reduced 1 month after BMT, and by 
3 months was within the pediatric control range. At 3 months after BMT, 
donor chimerism developed and was detected by the presence of 
2 B cell populations (inset; gated on mononuclear cells). The popula-
tions had high or low Lysotracker fluorescence, with a 50:50 distribution 
of B cells between the 2 populations. HLA typing confirmed the devel-
opment of 50% donor chimerism (not shown). (B) 7 patients on HPβCD 
therapy (individual use INDs) were analyzed. Patients 1–4 were ana-
lyzed pre-post i.v. HPβCD (arrows denote therapy initiation points), 
patients 5 and 6 were analyzed after HPβCD only, and patient 7 was 
analyzed pre-post intrathecal HPβCD delivery (no i.v. administration 
throughout the treatment period). (C) B cells isolated from the blood of 
patients 1–4 were analyzed to determine their levels of GSL storage. 
Total GSL levels were compared before and after HPβCD delivery for 
each patient and plotted individually (blue; error bars derived from 3 
independent HPLC analytical runs of the same samples). An average 
of the 4 patients was also plotted (green; error bars derived from the 
mean values for each patient). *P < 0.05; ***P < 0.001.
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trend in NPC1 patients was for 
older patients to have lower aver-
age MEFL values at the population 
level than pediatric NPC1 patients, 
implying a milder disease burden 
in older patients, as might be pre-
dicted. In contrast, the controls 
had a very tight distribution in 
pediatric individuals, which broad-
ened over time to a diverse range 
of values in the adult group. This 
may suggest that some individuals 
develop impaired lysosomal flux as 
they age, leading to an expansion 
of the lysosomal system. There 
was no simple age relationship, 
which suggests that this is not an 
inevitable consequence of aging. 
Alternatively, an expanded lyso-
somal system in some adults in 
the general population may reflect 
an increased rate of substrate flux 
through the lysosomal compart-
ment. This unexpected observa-
tion merits further investigation 
in the general population in order 
to better understand its basis and 
potential clinical significance.
However, the Lysotracker assay 
was useful in adults for monitoring individual changes over time, 
with patients serving as their own controls (Table 1 and ref. 3). 
As the biomarker would be used in clinical practice for monitor-
ing individual patients over time, not for population-based stud-
ies, this underscores its practical utility. When Lysotracker was 
compared with the NPC disease-specific oxysterol biochemical 
biomarker, there was a significant correlation with patients with 
lower MEFL values. Interestingly, a subset of patients with very 
high Lysotracker values did not have the predicted high level of 
triol species (assuming a linear relationship), suggestive of poten-
tially attenuated oxidative stress responses in these individuals 
and highlighting the need to use multiple biomarkers in NPC. 
Control and heterozygous carriers could be distinguished on the 
basis of mildly elevated oxysterol levels, whereas Lysotracker values 
overlapped between these 2 genotypes.
We calculated ASIS and found it to be significantly correlated 
with relative lysosomal volume. Scoring with ASIS may also rep-
resent a simple tool for stratifying patients for clinical trials or 
for monitoring disease progression. As the severity score used 
to calculate ASIS is derived from multiple neurological clinical 
measures (10), these data, in agreement with our findings in the 
Npc1–/– mouse (Figure 1), are suggestive of an association between 
storage in the CNS and in the hematopoietic system. Therefore, 
monitoring B cell lysosomal volume is a valid minimally invasive 
surrogate for storage levels in the CNS in NPC. These data also 
suggest that human B cell progenitors store progressively, such 
that this is reflected in the mature circulating B cell population, 
as the half-life of B cells in the blood is only 36 days (11). Most 
untreated NPC patients had increased relative lysosomal volumes 
over time, but significant decreases were observed in the miglustat-
treated groups, consistent with miglustat stabilizing/slowing the 
different tissues as disease progresses, so the use of peripheral bio-
markers is still informative and also minimally invasive for patients.
We then applied this assay to a multicenter, international pro-
spective study of 106 NPC patients, spanning a 5-year period. To 
our knowledge, this is the largest prospective study ever under-
taken in a neurodegenerative lysosomal disorder. Typically, bio-
marker validation involves analysis of multiple independent clini-
cal cohorts, each of sufficient size to provide sufficient statistical 
power, in order to draw conclusions about the biomarker’s prac-
tical utility. In the case of a rare lysosomal disease such as NPC, 
this is clearly not possible, due to small patient numbers. Instead, 
we combined patients from 3 independent clinical cohorts from 
3 countries to sufficiently power this study. Although this bio-
marker would be used in practice at the individual patient level, 
in the present study we began with population-based analysis to 
define the study cohort. We found that the clinical severity of the 
total NPC study cohort spanned the severity range, and addition-
ally revealed 6 discrete subgroups with differential rates of disease 
progression. Individual untreated patients longitudinally tracked 
an individual subgroup, which suggests that simply plotting total 
severity against age may have prognostic value, particularly in 
patients older than 5 years.
At the population level, the clear finding was that pediatric NPC 
patients had significantly elevated levels of Lysotracker staining in 
circulating B cells, minimally overlapping those of age-matched 
controls. Similar findings were made in 2 18-month-old Tay-Sachs 
disease patients compared with pediatric controls 0–6 years of 
age. As lysosomal hypertrophy is a universal feature of LSDs, it is 
logical to hypothesize, based on our data in more than 100 NPC1 
patients and 2 Tay-Sachs patients, that relative LE/Lys volume 
could represent a universal biomarker for lysosomal disorders. The 
Figure 5
Summary of major findings in the study.
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to highly specialized cell types. Clinical studies are planned to test 
this prospectively in a range of lysosomal disorders to determine 
clinical utility more broadly.
Methods
NPC1 mice. BALB/cNctr-Npc1m1N/J (Jackson Laboratory) mice (termed Npc1–/–) 
were maintained by heterozygote brother/sister matings and genotyped as 
previously described (22). The Npc1–/– mouse has a lifespan of 10–12 weeks, 
with neurological symptoms presenting at approximately 6 weeks of age. 
Mice were group housed in ventilated cages with irradiated food and bedding 
and autoclaved water available ad libitum. Control mice were Npc1+/+ mice 
generated from the same litters as the Npc1–/– animals. Blood and spleens were 
harvested from PBS-perfused mice under terminal anesthesia and analyzed 
for flow cytometry or biochemical analysis as previously described (9).
Clinical study cohort. The 106 total NPC patients in this study were from 
multiple independent international clinical cohorts from the United King-
dom, Germany, and the United States (29, 30, and 47 patients, respectively). 
A further 6 NPC1 patients treated with HPβCD were also studied (in addi-
tion to 1 patient on HPβCD therapy that was part of the US cohort, giving 
a total of 7 NPC1 patients on HPβCD treatment that were analyzed). The 
study cohort was composed of 52 untreated patients, 54 patients on miglu-
stat at time of first analysis, 41 heterozygous carriers, and 53 age-matched 
controls. There was no standardization between centers relating to the stage 
of disease when miglustat therapy was initiated, although dosing was stan-
dardized according to current clinical guidelines (23). In a subset of patients, 
treatment was initiated during the study, allowing for pre-post analysis of 
miglustat therapy. Longitudinal data was not collected on pediatric controls, 
only on adult heterozygous carriers and adult healthy volunteers.
We also studied a pair of twins with infantile-onset Tay-Sachs, who died of 
disease progression at 3 years of age. Analysis was performed at 16 months of 
age, at which time they had been on off-label miglustat therapy for 5 months.
HPβCD-treated patients. Patients 1 and 2 were started on i.v. HPβCD in 
April 2009 and dose escalated to 2,500 mg/kg, administered weekly. These 
2 patients were also receiving, by lumbar intrathecal injection, 175 mg 
HPβCD every 2 weeks starting in October 2010. Patient 3 and 4 were started 
on i.v. HPβCD in December 2010 and April 2011, respectively. They were 
dose escalated to 2,000 mg/kg, administered weekly. Patients 5 and 6 were 
started on i.v. HPβCD in January 2010 and started on intrathecal HPβCD 
in May 2010. At the time of blood sampling, they were receiving i.v. HPβCD 
at a dose of 2,900 mg/kg twice per week and intrathecal HPβCD at a dose of 
875 mg every 2 weeks. Patient 7 was on oral miglustat therapy (2 years) prior 
to commencing intrathecal HPβCD and remained on miglustat through-
out HPβCD treatment. Patient 7 was treated with HPβCD every 15 days and 
commenced with 175 mg HPβCD that was increased in single-dose steps 
(175, 250, 300, and 350 mg) up to a maintenance dose of 400 mg. Initially, 
this patient received all HPβCD doses through lumbar puncture with i.v. 
sedation; for the last 6 months of the study, HPβCD was delivered via an 
Ommaya intrathecal reservoir.
BMT of an NPC2 patient. The NPC2 patient presented as a neonate with 
hepatosplenomegaly and dysmorphic features. She developed progressive 
neurodevelopmental delay and unexplained pulmonary disease. At 14 
months of age, NPC2 was diagnosed based on filipin staining of skin fibro-
blasts and mutational analysis. 1 known NPC2 mutation was identified 
with no second mutation found, with intronic regions yet to be sequenced. 
The patient was deteriorating, and so BMT was performed at 18 months of 
age using an unaffected sibling donor, as efficacy had recently been report-
ed in another NPC2 case after BMT (18). Pre-BMT sampling and analysis 
in this study was performed prior to conditioning with immunosuppres-
sive drugs. She initially made a good recovery; however, donor chimerism 
developed after the initial response (reduced MEFL value), and she clini-
rate of disease progression in NPC1 patients (5, 12–14). Patients in 
whom pre-post analysis was performed exhibited the most marked 
decrease in storage, relative to the chronically miglustat treated 
group, which was relatively stable at the initiation of the study.
We also investigated the effects of 2 experimental therapies on 
this biomarker. NPC2 constitutes 5% of NPC cases (15) and is 
appropriate for BMT, as the NPC2 protein is a soluble, mannose-
6-phosphorylated protein amenable to secretion/recapture cross-
correction (16, 17). The efficacy of BMT was recently reported in 
an NPC2 patient (18). We therefore monitored an NPC2 patient 
pre-post BMT, and this biomarker revealed reduced storage in 
peripheral B cells after BMT (cross-correction at the early time 
point) and detected donor chimerism at 3 months after BMT. 
Before BMT, the patient was declining, with symptoms of respira-
tory compromise, ataxia, and slowed development of speech. After 
BMT, these symptoms improved, preceded by reduced Lysotrack-
er staining. When symptoms returned and repeat transplant was 
under consideration, Lysotracker values increased before the onset 
of clinical deterioration, which suggests that this may be a sensi-
tive biomarker for NPC2 disease.
HPβCD is an experimental drug that has shown benefit in 
mouse and feline models of NPC1 (19, 20), potentially by stimu-
lating lysosomal exocytosis, which has been demonstrated in vitro 
(21). There are currently 10 NPC1 patients worldwide undergo-
ing i.v. HPβCD therapy, of which 7 were included in this study. 
Patients previously treated with miglustat (patients 1–4 and 7; 
ref. 5) had reduced MEFL values, close to or within the normal 
range, prior to initiation of HPβCD therapy. Paradoxically, after 
HPβCD therapy, there was a pronounced increase in B cell Lyso-
tracker fluorescence. Patients 1–6, with i.v. exposure to the drug, 
developed elevated MEFL values that were similar to one another; 
all but 1 were above the upper limit of the general NPC1 patient 
population. Patient 7 never received HPβCD i.v.; the drug was only 
administered intrathecally. However, even this individual showed 
elevated MEFL values after approximately 1 year of HPβCD treat-
ment. The magnitude of this increase was less than in patients 
receiving i.v. HPβCD. These data suggest that intrathecal HPβCD 
treatment resulted in exchange of HPβCD into the peripheral cir-
culation, which was sufficient to lead to an increase in B cell MEFL 
values. This assay may serve as a useful surrogate of systemic expo-
sure to HPβCD treatment, regardless of the route of administra-
tion. We then investigated whether the increased MEFL values we 
observed after HPβCD treatment reflected enhanced lipid storage 
in response to HPβCD. When B cells from a subset of the patients 
were isolated and analyzed biochemically, GSL levels were higher 
than at the start of HPβCD therapy, suggestive of storage lipid 
redistribution to B cells in response to HPβCD. These data suggest 
that direct CNS delivery of HPβCD may be needed to minimize 
potential peripheral side effects, although even the patient receiv-
ing intrathecal drug (patient 7) showed elevated levels, albeit to a 
lesser extent than those receiving i.v. HPβCD.
The main findings of this study are summarized in Figure 5, 
including differential responses to therapies. Taken together, and 
based on lysosomal hypertrophy being a universal hallmark of 
LSDs, our present findings suggest that this biomarker may have 
broad utility as an aid to initial diagnosis (suspicion of an LSD), 
for monitoring disease progression in multiple LSDs, and for 
determining their differential responses to therapies. It remains 
to be determined whether this peripheral blood biomarker will be 
applicable in milder LSDs or in LSDs involving storage restricted 
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org). Graphs with error bars represent mean ± SD. A P value less than 0.05 
was considered significant.
Study approval. All animal studies were approved by the UK Home Office 
for the conduct of regulated procedures under licence (Animal Scien-
tific Procedures Act, 1986). Studies of NPC patients from the UK (06/
MRE02/85), Germany (S-032/2012), and the United States (06-CH-0186) 
were approved by the appropriate REC/IRB. Patient 7 in the HPβCD study 
was covered by ethics approval TRT585600308651 (Madrid, Spain). Writ-
ten informed consent and, if applicable, assent were obtained.
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cally declined after 6 months. She was given a repeat transplant 9 months 
after the initial BMT from the same donor and fully engrafted, leading 
to clinical improvement. At the end of the present study, the patient was 
stable and under continuous review.
Human blood collection and isolation of mononuclear cells. Venous blood was 
collected into EDTA tubes, maintained at room temperature, and analyzed 
within 72 hours (optimal for maintaining cell viability; data not shown). 
Consent or assent was obtained from all subjects, with ethical approval in 
place in each clinical center. Control samples were obtained by voluntary 
donation with informed consent, or from a commercial provider where 
informed consent/assent was given at the time of collection. The inves-
tigators were blinded to patient identity. Whole blood was loaded onto 
Histopaque-1077 (Sigma-Aldrich), and mononuclear cells were isolated 
according to the manufacturer’s instructions. The mononuclear fraction 
was washed twice with Dulbecco PBS (D-PBS) before counting.
Flow cytometry. Mononuclear cells (1 × 106, in duplicate) were incubat-
ed with PE-conjugated mouse anti-human CD19 antibody (clone LT19; 
Abcam) in D-PBS for 30 minutes on ice in the dark. The reaction was 
stopped with 100 μl 10% BSA, and cells were spun (5 minutes at 800 g), 
then either resuspended in 0.5 ml FACS buffer (0.1% BSA, 0.02M NaN3 
in 1× PBS) or stained with 1 ml of 200 nM Lysotracker-green DND-26 
(Invitrogen) in D-PBS for 10 minutes in the dark at room temperature. 
Cells were centrifuged for 5 minutes at 800 g, resuspended in 0.5 ml FACS 
buffer, and kept on ice for a maximum of 1 hour prior to flow cytomet-
ric analysis (BD Biosciences FACSCanto II). The cytometer was calibrated 
using Cytometer Setup and Tracking beads (BD), and compensation was 
performed using cells stained with Lysotracker and anti-mouse Comp-
Beads (BD) stained with PE antibody using FACSDiva software (BD). 
Samples were acquired with gating on singlets (FSC-H versus FSC-A) and 
CD19+ events. In total, 50,000 singlet events and 10,000 singlet gate CD19+ 
events were collected. The mean fluorescence of the CD19+ events was cal-
culated using FACSDiva software (BD). MEFL was calculated using 8-peak 
Rainbow calibration beads (BD) using the fluorescein equivalent values 
provided by the manufacturer. See Supplemental Figure 8 for details of 
FACS profile and analysis.
HPLC analysis. HPLC analysis of GSLs was performed according to previ-
ously published methods (24).
Oxysterol measurements. The methodology was according to published 
protocols (8). Lysotracker and oxysterol measurements were performed on 
the same clinical samples for each data point.
Statistics. Logistic regression models were used to compare proportions, 
Wilcoxon-Mann-Whitney and Kruskal-Wallis tests were used to com-
pare medians, and ANOVA was used to compare means. Linear regres-
sion models (including those with splines) were fitted with maximum 
likelihood methods; nonlinear regression models were fitted using least 
squares methods. Latent class finite mixture regression models were fitted 
using the R package flexmix (25) to define components of total clinical 
score as a function of age; the number of components was chosen by min-
imizing the Bayesian Information Criterion. Piecewise linear regression 
models were fitted using the R package SiZer (26). Adjusted P values for 
pairwise comparisons were obtained using the Benjamini-Hochberg cor-
rection (27). All calculations were performed in the R language and envi-
ronment for statistical computing (version 2.14.2; http://www.R-project.
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